Request a Call

Request a Call from a
representative

This section of the website is intended for UK AND IRELAND Healthcare Professionals only.
If you are not a Healthcare Professional from the UK or IRELAND please click here

•
•
Cost calculator
usc head image

Information for:

UK & IRELAND HEALTHCARE PROFESSIONALS

Click here if you are a healthcare professional and would like more information on Pradaxa® (dabigatran etexilate)

UK & IRELAND HEALTHCARE PROFESSIONALS WEBSITE

Information intended for:

PATIENTS PRESCRIBED PRADAXA®/ MEMBERS OF THE PUBLIC IN THE UK & IRELAND

Click here for more information on Pradaxa®

MORE INFORMATION ON PRADAXA

PC-GB -101423 V1 January 2021

© 2021 Boehringer Ingelheim Ltd. UK.
All rights reserved.

Calculate your potential cost savings
with Pradaxa (dabigatran etexilate)®
versus other NOACs

Cost

How much could you save by prescribing Pradaxa® (dabigatran etexilate) for your patients with non-valvular atrial fibrillation versus other NOACs? Use the simple cost calculator below to find out. 

Calculator

 

If you switch your eligible patients to Pradaxa®, your potential yearly savings are

 

£0.00

Prices based on NHS list price.1
Annual savings per patient are calculated by multiplying the difference in the daily price of each drug relative to Pradaxa® by 365. The total savings are calculated by multiplying the savings per patient on apixaban, rivaroxaban and edoxaban by the number of patients receiving them, respectively. This calculator assumes that all of your NOAC patients are suitable for Pradaxa®. Please refer to the Pradaxa® Summary of Product Characteristics to ensure your patient is appropriate for Pradaxa® prior to prescribing.2,3

See more information on NOAC NHS list prices here
Abbreviations

NOAC — non-vitamin K antagonist oral anticoagulant

References
  1. MIMS.co.uk (accessed July 2020).
  2. Pradaxa® 150mg hard capsules Summary of Product Characteristics.
  3. Pradaxa® 110mg hard capsules Summary of Product Characteristics.
PC-GB-101176 V1 | August 2020

Pradaxa® (150mg and 110mg hard capsules) is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular AF, with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; heart failure (NYHA Class ≥II); diabetes mellitus; hypertension.a,b

Praxbind® is a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa® (dabigatran etexilate) when rapid reversal of its anticoagulant effects is required: • For emergency surgery/urgent procedures • In life-threatening or uncontrolled bleeding.c

For more information, or to access the current prescriber guide and summary of product characteristics, please visit www.medicines.org.uk/emc (UK) or www.medicines.ie (Ireland).

Adverse events should be reported. 
UK: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) or by email to PV_local_uk_ireland@boehringer-ingelheim.com.
IE: Reporting forms and information can be found at www.hpra.ie/homepage/about-us/report-an-issue. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 01 291 3960 or by email to PV_local_uk_ireland@boehringer-ingelheim.com.

References:

  1. Pradaxa® 110mg hard capsules Summary of Product Characteristics

  2. Pradaxa® 150mg hard capsules Summary of Product Characteristics

  3. Praxbind® Summary of Product Characteristics

Disclaimer

You are about to leave the Boehringer Ingelheim site for a site not created, managed or maintained by Boehringer Ingelheim.

Boehringer Ingelheim hopes that this link will be of interest and use to visitors, but it accepts no liability in relation to the website or its contents and gives no warranty as to the accuracy or completeness of information, data or reports on the website, to the fullest extent that any such liability may be lawfully excluded. Nor does Boehringer Ingelheim necessarily endorse or support any content on the third party website or any further links from their website.

Click OK to acknowledge and accept this disclaimer and to access the website.

Ok Cancel